Komori
Ono Pharmaceutical (4528) · TargetAdvancedLatest General Meetings of Shareholders (2026-05-21): "Restated"

Policy of making cancer treatment and supportive care important strategic areas

First written in FY2016. 7 of 12 entries say "Restated". Latest entry: 2026-05-21.

12entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2017RestatedFY2018RestatedFY2023-Q2 – FY2024AdvancedFY2025-H1 – FY20252016: 220162017: 220172018: 120182019: 020192020: 020202021: 120212022: 120222023: 120232024: 220242025: 120252026: 12026
Same theme, other companies
Focus on oncology drug developmentA theme 5 companies write about · 0 as a headwind · 4 as a tailwind

3 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-05-21RestatedGeneral Meetings of Shareholders

    「In drug discovery research, we have designated oncology, immunology and inflammation, and neurology as priority areas with high unmet medical needs. In each area, we seek to deepen our understanding of human disease biology and discover new drugs capable of meeting medical needs.」

    The policy of focusing on oncology, immunology and inflammation, and neurology was reaffirmed.
  2. FY2025AdvancedAnnual report

    「In particular, because the cancer field has high medical needs, the company positions it as an important strategic area and is further strengthening it by adding Deciphera’s pipeline.」

    The company has incorporated concrete measures to expand its policy of making the cancer field an important strategic area by adding Deciphera’s pipeline.
  3. FY2025-H1AdvancedAnnual report

    「In particular, because the cancer field has high medical needs, the company positions it as an important strategic area and is further strengthening it by adding Deciphera’s pipeline.」

    The company has taken concrete steps to further strengthen its policy of making the cancer field an important strategic area by adding Deciphera’s pipeline.
  4. FY2024RestatedAnnual report

    「In particular, because the cancer field has high medical needs, the company positions it as an important strategic area.」

    The company has reaffirmed its policy of making the cancer field an important strategic area with high medical needs.
  5. FY2023RestatedAnnual report

    「In particular, because the cancer field has high medical needs, the company positions it as an important strategic area.」

    The research and development policy reaffirms the policy of making the cancer field an important strategic area with high medical needs.
  6. FY2023-Q2RestatedAnnual report

    「In particular, because cancer treatment is an area with high medical needs, the company positions it as an important strategic area.」

    The company has reaffirmed its policy of making cancer treatment an important strategic area with high medical needs.
  7. FY2022-Q2ReframedAnnual report

    「In particular, because cancer treatment is an area with high unmet medical needs, the company positions it as an important strategic area.」

    The current research and development policy describes “the field of cancer treatment” as an important strategic area, rather than using the previous wording that included cancer treatment and supportive care.
  8. FY2018RestatedAnnual report

    「In particular, because cancer treatment and supportive care are areas with high unmet medical needs, the company positions them as important strategic areas and aims to contribute to comprehensive pharmacological treatment for cancer patients.」

    The company has reaffirmed its policy of making cancer treatment and supportive care important strategic areas and contributing to comprehensive pharmacological treatment.
  9. FY2018-Q2ReframedAnnual report

    「In particular, because cancer treatment and supportive care for cancer patients, including relief from pain and nausea caused by anticancer drugs, are areas with high unmet medical needs, the company positions them as important strategic areas and aims to contribute to comprehensive pharmacological treatment for cancer patients, including supportive care.」

    Although the terminology has changed from the previous expression “supportive care” to “supportive care” in the current wording, the substance of making cancer treatment and related areas important strategic areas has been maintained.
  10. FY2017RestatedAnnual report

    「In particular, because cancer treatment and supportive care are areas with high unmet medical needs, the company positions them as important strategic areas and aims to contribute to comprehensive pharmacological treatment for cancer patients, including supportive care.」

    The company has reaffirmed its policy of making cancer treatment and supportive care important strategic areas and contributing to comprehensive pharmacological treatment.
  11. FY2017-Q2RestatedAnnual report

    「In particular, because cancer treatment and supportive care are areas with high unmet needs, the company positions them as important strategic areas and aims to contribute to comprehensive pharmacological treatment for cancer patients, including supportive care.」

    The company has reaffirmed its policy of making cancer treatment and supportive care important strategic areas and contributing to comprehensive pharmacological treatment.
  12. FY2016First statedAnnual report

    「Because cancer treatment and supportive care are areas with high unmet needs, the company positions them as important strategic areas and aims to contribute to comprehensive pharmacological treatment for cancer patients, including supportive care.」

    The company identifies cancer treatment and supportive care as priority areas and aims to contribute to comprehensive pharmacological treatment.
Moved together

"Pursuing new drug discovery modalities, including cell therapies and mid-sized molecules" moved the same way as this thread, in the same document, in 2 of its 12 moves.

222222★123456
  1. ★This thread
  2. 1Pursuing new drug discovery modalities, including cell therapies and mid-sized molecules2×
  3. 2Expansion of the development pipeline and continued launches of new drugs2×
  4. 3In-Licensing Promising New Drug Candidate Compounds and Accelerating Clinical Trials2×
  5. 4Global business expansion and international launches2×
  6. 5Risk of declining sales due to competing and generic products2×
  7. 6Acquisition of Deciphera Pharmaceuticals to acquire its pipeline and in-house sales capabilities in Europe and the United States2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-05-21: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Policy of making cancer treatment and supportive care important strategic areas | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori